GlassScriptPhysician profile
Dylan Duncan Thomas
NPI 1093058919
$17,376.26
in general payments reported to CMS, 2019-2025
6 companies · $300 in 2025
The $300 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114 · 2020: $107 · 2022: $131 · 2023: $563 · 2024: $16K · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Consulting Fee: $1,350 · Food and Beverage: $411 · Honoraria: $300 · Education: $226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,737.50 |
| Consulting Fee | $1,350.00 |
| Food and Beverage | $410.74 |
| Honoraria | $300.00 |
| Education | $225.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $16,087.50 | 2024 | |
| Tandem Diabetes Care, INC. | $589.82 | 2019-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Chiesi USA, INC. | $300.00 | 2025 | Mycapssa |
| Novo Nordisk INC | $225.89 | 2023 | Ozempic |
| Dexcom, INC. | $138.10 | 2022-2024 | Dexcom G6 Transmitter |
| Depuy Synthes Sales INC. | $34.95 | 2023 | Na |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dylan Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.